Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag Gets CE Mark for Intestinal Parasites Test

NEW YORK – Finnish molecular diagnostics company Mobidiag said today that it has received CE-IVD marking for its Novodiag Stool Parasites test for the detection of intestinal parasites from stool samples.

The Novodiag Stool Parasites syndromic test combines real-time PCR and microarray technologies to detect more than 95 percent of intestinal parasites, the firm said. Its test detects the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples.

Espoo, Finland-based Mobidiag said that its test is designed to run on demand using its automated Novodiag platform, which allows direct analysis of a patient sample in a disposable cartridge. The stool parasites test provides results in 90 minutes with less than five minutes hands-on time, and is suitable for use in laboratories and hospitals.

"Parasitic diseases contribute significantly to the burden of infectious diseases worldwide and current diagnostic methods such as microscopy are labor-intensive and require a high level of skill," Mobidiag CEO Tuomas Tenkanen said in a statement.

As the fourth test on the company's platform, Novodiag Stool Parasites joins Novodiag C. difficile, Novodiag Bacterial GE+, and Novodiag CarbaR+ among the company's products.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.